Credits: Canva
Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.
Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".
In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.
Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.
Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.
The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.
Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.
Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.
Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.
Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.
However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.
Credit: iStock
COVID-19 infections have resurfaced in India, with Andhra Pradesh reporting two deaths and several active cases, prompting health authorities to step up surveillance and preparedness measures.
A 52-year-old man from Kadapa's Rajampet area, who tested positive for COVID-19 after developing fever and cough, died while undergoing treatment at Christian Medical College (CMC), Vellore.
In another case, a 43-year-old man from Kadapa, who was admitted to the Government General Hospital with health complications, tested positive and later died while receiving treatment in the COVID-19 Intensive Care Unit.
A 25-year-old medical student from Kadapa Medical College has also tested positive for the virus and is currently undergoing treatment through home isolation. Several more cases have also been reported.
Doctors say they have seen a rise in COVID-19 cases over the past few weeks.
Dr. Lancelot Pinto, Consultant Pulmonologist and Epidemiologist at the PD Hinduja Hospital, Mumbai, told HealthandMe that SARS-CoV-2 has frequently been detected in patients presenting with viral respiratory infections.
"So when we send throat swabs in the context of a viral respiratory infection, we have detected SARS-CoV-2 as the causative organism often. It doesn't seem that this is a more virulent strain based on our experience so far. But in those who are immunocompromised, who are vulnerable because of their health risks, it can cause severe disease."
While the exact variant behind these cases has not yet been confirmed and samples have been sent for genome sequencing, experts say the virus currently circulating in India is largely made up of Omicron sub-lineages.
"The virus currently circulating in India is largely made up of Omicron sub-lineages, which generally cause milder illness than earlier variants, though they remain highly transmissible," Dr. Neha Rastogi, Senior Consultant, Infectious Diseases, Fortis Memorial Research Institute, Gurugram, told HealthandMe.
According to Dr. Pinto, viruses are capable of triggering what is known as an inflammatory cascade—a strong immune response that can sometimes contribute to severe illness.
"This cascade is such that there's a strong immune response to the virus that can sometimes be detrimental to humans, causing severe disease. We also know that any viral infection, however innocuous it may seem, has the potential of increasing your cardiovascular risk."
He explained that viral infections can also increase cardiovascular risk, meaning people already at risk of heart-related complications may experience poorer outcomes.
"And therefore, those who are at an increased risk of cardiovascular events could suffer from poor outcomes in the context of any viral infections."
Another concern, he said, is the limited availability of antiviral medicines.
"What has been concerning, though, is the difficulty of procuring antivirals at present. So drugs such as remdesivir and paxlovid are not easily available. And therefore, we are not able to offer it to vulnerable and high-risk individuals. And I hope this gets fixed in the near future."
Although the circulating Omicron sub-lineages generally cause milder illness, they can still lead to severe disease in vulnerable individuals.
Those most at risk include:
Despite the lower overall severity of the current variants, health experts say vigilance remains important. To reduce the risk of infection, people should stay up to date with COVID-19 vaccinations, wear masks in crowded indoor settings, maintain hand hygiene, ensure good ventilation, and avoid close contact when unwell.
Anyone experiencing symptoms such as fever, cough, or breathlessness should get tested and seek timely medical advice.
"If you are a high-risk individual and suffer from diseases such as diabetes, high blood pressure, chronic kidney disease, chronic liver disease, or respiratory disease such as COPD, this is the time to be a little cautious about exposing yourself to those who are ill, trying and avoiding crowds, trying and avoiding places where there's a conglomeration of individuals together and easy to pick up viruses. Mask up with a high-efficiency mask if it's feasible, especially if you are exposed to such kind of situations," Dr Pinto said.
For people without these underlying conditions, he said the virus appears to behave much like other seasonal respiratory viruses.
"For the average person who does not have a high risk in terms of these comorbidities, it does appear that this virus behaves just like any other seasonal influenza virus or any other seasonal virus."
Credit: iStock
Europe's record-breaking June heatwave led to an estimated 10,000 excess deaths across 27 countries, with older adults accounting for the overwhelming majority of fatalities, according to official data.
Data published by EuroMOMO—a mortality monitoring network supported by the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO)—showed around 10,000 excess deaths during the week of June 22-28, when extreme heat peaked across France, Spain, Britain and several other European countries.
More than 9,000 of these deaths were among people aged 65 years and older.
"To have this kind of excess at this time of year is unusual. It's really high," Lasse Vestergaard, Chief Physician at Denmark's Statens Serum Institut, which hosts EuroMOMO, was quoted as saying to Reuters news agency.
"It is difficult to explain this high excess mortality by anything but the extreme heat," he added.
The figures are based on all-cause mortality, meaning they include deaths from all causes rather than only those officially classified as heat-related.
Scientists have also said the late-June heatwave would have been "virtually impossible" without human-caused climate change, which is making extreme heat events more frequent and intense.
A separate analysis by researchers from the London School of Hygiene & Tropical Medicine (LSHTM), Imperial College London, and the Met Office estimated more than 2,700 excess heat-related deaths during the May and June 2026 heatwaves in England and Wales.
Researchers estimated:
The study found that around 42% of the total heat-related deaths across both heatwaves were attributable to human-caused climate change.
According to the report, climate change increased daytime maximum temperatures across England and Wales by 3°C to 4°C.
The analysis estimated that climate change was responsible for:
Both heatwaves shattered long-standing temperature records, with 35.1°C recorded in West London in May and 37°C in East Anglia in June.
"We are still in the first half of summer in the UK and large parts of England and Wales have already experienced two record-breaking heatwaves," said Dr Malcolm Mistry, Assistant Professor in Climate and Geo-spatial Modelling at LSHTM.
According to the Copernicus Climate Change Service (C3S), June 2026 was the hottest June ever recorded in western Europe and the second warmest globally.
The record temperatures were driven in part by the highest sea surface temperatures ever recorded for June.
"Heatwaves like this are what we expect to see in a changing climate," said John Kennedy, Head of Climate Information at the World Meteorological Organization (WMO).
He noted that Europe has warmed by around 2°C over the past 50 years, making it the world's fastest-warming continent and increasing the frequency of extreme heat events.
Extreme heat is often called the "silent killer" because heat-related deaths are frequently underreported. Globally, an estimated 489,000 people died from heat-related causes each year between 2000 and 2019, according to modeled estimates.
Heat stress develops when the body absorbs more heat than it can release. While sweating and increased blood flow to the skin normally help regulate body temperature, these cooling mechanisms become less effective during prolonged periods of intense heat—especially when humidity is high.
According to Lachlan McIver, Health Advisor at the WHO-WMO Climate and Health Joint Office, older adults, infants, pregnant women, outdoor workers, people experiencing homelessness, and those with chronic illnesses are at the greatest risk, although prolonged extreme heat can affect anyone.
Credit: AI
The World Health Organization (WHO) Southeast Asia is actively attempting to phase out mercury-infused dental fillings. The move comes as a way to help countries gradually replace them with mercury-free alternatives, citing environmental concerns and long-term public health goals.
Commonly known as dental amalgam or silver fillings, mercury-containing dental fillings have been used by dentists for more than 150 years as they are durable, affordable, and effective.
In partnership with the United Nations Environment Programme (UNEP), WHO Southeast Asia continues to implement a project, running from 2023 to 2026, in order to help countries phase down the use of dental amalgam while improving the management of mercury-containing waste generated by dental clinics.
The initiative supports commitments made under the Minamata Convention on Mercury - a global treaty aimed at reducing mercury pollution.
“Dental amalgam has served dentistry well for decades, but we now have an opportunity to transition towards safer and more environmentally sustainable alternatives,” WHO South-East Asia said while announcing the regional initiative.
The agency noted that the goal is not only to reduce mercury use in dentistry but also to strengthen mercury waste management systems.
Also read: How Diabetes Increases The Risk Of Gum Disease? Key Signs and Prevention Tips
Although major health authorities, including WHO and many national dental organizations, maintain that amalgam fillings are generally safe for most people; mercury remains a toxic substance that can accumulate in the environment.
Small amounts of mercury may be released during the placement, removal, or disposal of fillings, eventually entering water bodies and the food chain if not managed with care.
The WHO states that mercury is one of the chemicals of major public health concern because of its harmful effects on the nervous, digestive and immune systems, particularly among unborn babies and young children.
The global strategy focuses on reducing future use rather than encouraging people to remove restorations that are already functioning well.
Modern tooth-coloured composite resins, glass ionomer cements and other mercury-free materials are increasingly replacing dental amalgam across the world.
Besides being aesthetically preferable, these materials are also environmentally friendly. But composite fillings can be more expensive, warrant greater technical expertise, and may not always be suitable in every situation.
This is why WHO is promoting a phased approach, allowing countries to strengthen dental services, train oral care professionals and improve access to affordable alternatives before completely eliminating mercury-containing fillings from dentistry.
The WHO Southeast Asia initiative aligns with the Minamata Convention, under which countries recently agreed to phase out dental amalgam globally by 2034.
For patients, experts stress there is no need to replace existing amalgam fillings solely because they contain mercury if they remain intact and functional. Instead, the focus is on ensuring that future dental care becomes completely mercury-free to protect public health and the environment.
© 2024 Bennett, Coleman & Company Limited